• 2015-02-06
    2015
    Release of PharmML 0.6 Major extensions compared to the first public release, v. 0.2.1 (November 2013), are: - Discrete data models - PK macros - DDEs and many other changes/extensions. Please, see chapter 10 in the spec document for the...
  • 2015-01-20
    2015
    Simulx is a function of the R package mlxR. Simulx allows one to simulate complex models for longitudinal data by interfacing the C++ MlxLibrary with R. http://simulx.webpopix.org/ Learn how to use Simulx with many illustrative examples...
  • 2015-03-16
    2015
    The first public DDMoRe course launches a series of comprehensive face-to-face courses introducing the principles of model-informed drug development, covering a range of therapeutic areas, via the newly-developed DDMoRe interoperability...
  • Milestone
    2014-10-31
    2014
    The Model Repository from the Drug Disease Model Resources (DDMoRe) consortium provides a home to a collection of computational models of disease and drug action that have been used in pharmaceutical and/or academic research. This...
  • 2014-04-23
    2014
    7th Noordwijkerhout Symposium on Pharmacokinetics, Pharmacodynamics and Systems Pharmacology, Noordwijk, 2014 DDMoRe was running a 2 hours hands-on workshop on Wednesday 23rd April 2014, 10:00 - 12:00 as an introduction to the current...
  • Milestone
    2013-11-14
    2013
    MDL
    Modelling Description Language The Modelling Description Language (MDL) is a human writeable and human readable language to express the information required to describe pharmacometric models and tasks using these models. The specification...
  • Milestone
    2013-11-28
    2013
    MDL-IDE The Modelling Description Language (MDL) is a human writeable and human readable language to express the information required to describe pharmacometric models and the tasks that utilise these models. The MDL Integrated...

About DDMoRe

The Drug Disease Model Resources (DDMoRe) consortium builds and maintains a universally applicable, open source, model based framework, intended as the gold standard for future collaborative drug and disease Modelling & Simulation.

Modelling and Simulation is a technology providing the quantitative basis for informed decision making across all stages of pharmaceutical drug development. This model-based drug development is accepted as a vital approach in understanding patients’ drug-related benefit and risk. Information from a wide array of sources to describe and predict the behaviours of complex disease/biological systems and drug actions can be integrated in models.

Before the DDMoRe consortium, a lack of common tools, languages and ontologies for Modelling and Simulation limited the access to stored information which created significant gaps in the way knowledge could be exploited within drug development.  The DDMoRe consortium is generating a public drug and disease model repository as well as an open source interoperability framework containing standards and tools to cover the identified gaps in the Modelling and Simulation software ecosystem. The DDMoRe project’s standards and tools – intended as the gold standard for future collaborative drug and disease Modelling and Simulation - will be supported by comprehensive training and will be made publicly accessible.

Key Objectives

  • Enable efficient exchange and integration of modelling activities.
  • Outputs across software tools, disciplines and departments within and among organizations.
  • Provide standards applicable to all areas of Modelling and Simulation, appropriate for adoption and use by all relevant domain stakeholders.
  • Development of an open, publicly available, free-to-use model repository, based on the developed standards, to promote the re-use of models.
  • The model repository may evolve into a global reference for model-based efforts in the therapeutic areas Diabetes, Oncology and Other Diseases.
  • Provide support for education and training in drug/disease Modelling and Simulation.
 

© 2012 | DDMoRe, all rights reserved.